Artivion AORT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Artivion (AORT)
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
Key Insights
Critical company metrics and information
Latest Closing Price
$24.18Market Cap
$1.01 BillionPrice-Earnings Ratio
-75.56Total Outstanding Shares
41.73 Million SharesTotal Employees
1,500Dividend
$0.03 Per Share QuarterlyIPO Date
February 11, 1993SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeType
Common StockHeadquarters
1655 roberts boulevard n w, Kennesaw, GA, 30144Homepage
https://www.artivion.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $22.24 Million |
Net Cash Flow From Operating Activities, Continuing | $22.24 Million |
Net Cash Flow, Continuing | $-3.75 Million |
Exchange Gains/Losses | $-1.73 Million |
Net Cash Flow | $-5.48 Million |
Net Cash Flow From Investing Activities, Continuing | $-28.19 Million |
Income Statement
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit, Deferred | $-1.51 Million |
Operating Expenses | $209.91 Million |
Research and Development | $28.45 Million |
Revenues | $388.54 Million |
Income/Loss From Continuing Operations Before Tax | $-7.51 Million |
Income Tax Expense/Benefit, Current | $7.36 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income/Loss | $-26.28 Million |
Comprehensive Income/Loss Attributable To Parent | $-26.28 Million |
Other Comprehensive Income/Loss | $-26.28 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $446.08 Million |
Other Current Assets | $210.31 Million |
Equity Attributable To Noncontrolling Interest | $0 |
Fixed Assets | $36.40 Million |
Liabilities | $512.90 Million |
Other Current Liabilities | $30.51 Million |
Historical Dividends
Current dividend: $0.03 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Oct 22, 2015 | Dec 18, 2015 | Dec 11, 2015 | $0.03 | Quarterly |
Jul 22, 2015 | Sep 18, 2015 | Sep 11, 2015 | $0.03 | Quarterly |
May 21, 2015 | Jun 19, 2015 | Jun 12, 2015 | $0.03 | Quarterly |
Feb 13, 2015 | Mar 20, 2015 | Mar 13, 2015 | $0.03 | Quarterly |
Oct 23, 2014 | Dec 19, 2014 | Dec 12, 2014 | $0.03 | Quarterly |
Jul 30, 2014 | Sep 19, 2014 | Sep 12, 2014 | $0.03 | Quarterly |
Recent Headlines From The Web
Latest news, press releases, and media coverage about AORT from trusted financial sources
â“’ 2025 Financhle. All Rights Reserved.